Why the study?
This review aimed to investigate the factors, mechanisms, laboratory evaluation methods, and clinical implications of clopidogrel resistance, its correlation with harmful cardiovascular events, and potential solutions including new-generation alternative antiplatelet agents.
Clopidogrel resistance, primarily driven by inadequate active metabolite generation due to genetic or metabolic factors, can be potentially managed by utilizing higher doses or alternative P2Y12 inhibitors.
Answers are grounded in this paper and cite their sources.
May guide alternative P2Y12 use in resistant patients; leaves open need for randomized outcome trials before adoption.
Clopidogrel, a drug belonging to the thienopyridine class of antiplatelet agents, has been utilized either as a standalone medication or in combination with aspirin for averting vascular complications in patients afflicted with atherothrombotic conditions. The selective and irreversible blockade of the P2Y12 receptor by clopidogrel makes it a potent inhibitor of platelet activation and aggregation. In patients with acute coronary syndromes or undergoing percutaneous interventions, combining clopidogrel with aspirin is a crucial approach to antiplatelet therapy. The aim of this review article is to investigate the factors that contribute to clopidogrel resistance, mechanisms involved in clopidogrel resistance, evaluate it through laboratory methods and clinical implications of clopidogrel resistance. Additionally, the article explores the clinical importance of Clopidogrel Resistance and its correlation with harmful cardiovascular events. The paper concludes by proposing potential solutions to this resistance and suggesting the usage of alternative antiplatelet from the new generation.
No takes yet. Share an insight, caveat, or question.
Raghavendra et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: